Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Change in Accured Expenses (2016 - 2025)

Neuroone Medical Technologies' Change in Accured Expenses history spans 11 years, with the latest figure at -$619376.0 for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 33.69% year-over-year to -$619376.0; the TTM value through Dec 2025 reached -$210526.0, down 394.42%, while the annual FY2025 figure was -$54442.0, 435.77% down from the prior year.
  • Change in Accured Expenses reached -$619376.0 in Q4 2025 per NMTC's latest filing, down from $302463.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.7 million in Q3 2022 to a low of -$1.4 million in Q1 2023.
  • Average Change in Accured Expenses over 5 years is -$28344.6, with a median of $53193.5 recorded in 2025.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 1227.97% in 2022, then tumbled 7447.94% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at -$317456.0 in 2021, then rose by 3.57% to -$306125.0 in 2022, then plummeted by 69.4% to -$518584.0 in 2023, then increased by 10.66% to -$463292.0 in 2024, then crashed by 33.69% to -$619376.0 in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Change in Accured Expenses are -$619376.0 (Q4 2025), $302463.0 (Q3 2025), and $73839.0 (Q2 2025).